Drugs / Polyglucosamine L112
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT04375696 | Apr 2020 → Dec 2021 | — | Certmedica International GmbH | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05022732 | May → Aug 2020 | obesity disorder | Azienda di Servizi alla Persona di Pavia | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Polyglucosamine L112 | “Polyglucosamine L112 (750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients)” NCT05022732 ↗ |